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Predicting length of treatment for neonatal abstinence syndrome in methadone exposed 
neonates. 
 
Neil S SELIGMAN MD, Nicole SALVA, Edward J HAYES MD MSCP, Kevin C DYSART 
MD, Edward C PEQUIGNOT MS, Jason K BAXTER MD MSCP 
 
Abstract 
Objectives: To identify maternal variables predicting length of treatment for neonatal abstinence 
syndrome (NAS).  
Study Design: Retrospective cohort study of infants treated for NAS during 2000-2006 whose 
mothers were on methadone maintenance at delivery.  Mixed effects linear regression was used 
to examine the interaction of maternal and neonatal variables with length of treatment.  
Results: Of 204 neonates, born to methadone exposed mothers, average dose at delivery was 127 
mg daily (25-340 mg) with median length of treatment 32 days (1-122 days).  Trimester of initial 
exposure (p=0.33), methadone dose at delivery (p=0.198), BMI (p=0.31), antidepressant use 
(p=0.40), cigarette use (p=0.76), race (p=0.78) and maternal age (p=0.84) did not predict length 
of treatment.  In the multivariate analysis gestational age at delivery and benzodiazepine use 
were significant predictors of length of treatment.   
Conclusions: Later gestational age and concomitant benzodiazepine use were associated with 
longer treatment.  
Key Words: antenatal methadone; neonatal withdrawal; drug abuse 
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Introduction 
 Illicit drug use is prevalent among reproductive age women.  A survey of combined data 
from 2005 and 2006 reported that 10% of women of childbearing age used illicit drugs (1).  Of 
these women, 4% disclosed illicit drug use in the past month while pregnant (1).  Intrauterine 
exposure to opiates may lead to neonatal withdrawal characterized by central nervous system 
irritability, gastrointestinal dysfunction, and autonomic signs (2).  The constellation of findings is 
termed neonatal abstinence syndrome (NAS).   
Management of opioid-dependence with methadone has been used since the 1960’s to 
improve maternal and neonatal outcome (3).  Methadone maintenance is associated with more 
prenatal care, improved fetal growth, and increased likelihood of discharge to parents’ care (4).  
Despite its benefits, withdrawal from methadone is more severe than withdrawal from heroin, 
which translates into lengthier hospital stays causing a substantial burden on families (5).  In 
large methadone treatment programs, treatment of NAS in otherwise healthy neonates in the 
neonatal intensive care unit is resource intensive and a substantial expense.  At our institution, 
NAS occurs in 62-74% of neonates exposed to opiates in utero (6), and length of treatment for 
these neonates ranges from 7-49 days (7).  These treatment statistics compare with results 
reported at other institutions. 
Efforts to reduce the severity of withdrawal have largely focused on methadone 
administration and treatment of NAS.  Initiating pharmacologic treatment for NAS decreases the 
duration of symptoms (2) but does not subjugate the necessity to decrease the severity of 
withdrawal through antenatal interventions.  The majority of literature on methadone 
administration is concentrated on dosage and the findings regarding an association between 
maternal methadone dose and the severity of neonatal withdrawal conflict (6, 8, 9, 10, 11, 12, 13, 
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14, 15).  The optimal dose remains a topic of clinical debate.  Methadone dose is only one aspect 
of treating opiate addiction.  The role that other aspects of maternal treatment play in mitigating 
or potentiating the severity of neonatal withdrawal is largely unstudied.  The purpose of this 
study was to determine which maternal variables predict the length of treatment for NAS in 
methadone exposed neonates.   
 
Material and Methods 
 Institutional review board approval was obtained to conduct a retrospective chart review.  
The hospital medical records database was queried using the International Classification of 
Diseases codes for antepartum drug dependence (648.33), maternal drug dependence with 
delivery (648.31), and opioid dependence continuous use (304.01).  The inpatient medical 
records of methadone maintained women who delivered  between January 1st, 2000 and June 
30th, 2006 and had urine drug screen (UDS-9) positive for methadone within the two weeks 
preceding the delivery date were reviewed.  The “drugs of abuse” (DAU) screen does not test for 
methadone.  Records were also reviewed for women whose DAU at delivery was negative for 
opiates if there was documentation of methadone use in the patient’s medical record.  Neonatal 
charts were reviewed and only neonates diagnosed with NAS and their mothers were included in 
the study.  Additional information was obtained from outpatient obstetrical clinic records, the 
Childrens Rehabilitation Hospital records, and from General Electric Medical Systems 
Quantitative Sentinel.  Patients were excluded if the length of neonatal treatment could not be 
determined or if the neonate was enrolled in a coinciding NAS treatment study with an 
experimental drug.  Stillbirths and deliveries at less than 23 weeks were also excluded.   
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 In Philadelphia, Pennsylvania, only Thomas Jefferson University Hospital offers a 
comprehensive program for methadone stabilization of opiate addicted pregnant women which 
has been described previously (6).  The stabilization protocol was an initial methadone dose of 
20-30mg orally followed by 5-10mg every 6 hours as needed for withdrawal symptoms.  On 
each consecutive day, the new dose was the total dose of methadone administered in the prior 24 
hours.  Patients were discharged when they had been stable without additional doses of 
methadone for at least 12-18 hours after the last dose.  Pregnant women that were not admitted 
for methadone stabilization were assumed to be on methadone at the time of conception for the 
purpose of determining the trimester of initial exposure to methadone and the length of exposure 
to methadone.   
 All of the neonates were delivered at Thomas Jefferson University Hospital.  The 
neonates were transferred to the newborn nursery in the absence of other co-morbidities.  An 
objective score was assigned every eight hours for the first 72 hours of life according to the 
Finnegan scoring system (16).  An average of the three scores greater than 24 was criteria for 
treatment of NAS.  Standard of care treatment at Thomas Jefferson University Hospital consists 
of an initial dose of morphine 0.4 mg/kg/day (in the form of neonatal opium solution) in 6 
divided doses with dose escalation of 10%/day for Finnegan scale scores greater than 24 total on 
either 2 or 3 measures.  Maximum dosage was 2 mg/kg/day, after which adjunctive treatment 
with phenobarbital was initiated.  Infants were weaned from neonatal opium solution (NOS) 
once they demonstrated control of their NAS as measured by the Finnegan scale for 48 hours.  
Daily dose was weaned by 10% every 48 hours as the infant tolerated.  If an infant required 
rescue therapy the equivalent of one extra dose of NOS was given. Infants are discontinued from 
treatment when they demonstrated no signs of abstinence as measured on the Finnegan scale and 
 7 
reach a dose of 0.15 mg/kg/day.  Length of treatment was defined as the duration of 
pharmacologic treatment for NAS.   
The following variables were compared to length of treatment for NAS: length of 
exposure to methadone, trimester of initial exposure, methadone dose at delivery, maternal body 
mass index (BMI), antidepressant use, benzodiazepine use, tobacco use, alcohol use, gestational 
age at delivery, race, and maternal age.  Methadone dose at delivery was defined as the 
methadone dose within the 24 hours prior to delivery.  Maternal BMI was calculated using 
weight at delivery.   First urine drug screen (UDS) was defined as the first available UDS more 
than two weeks prior to delivery.  Last UDS was defined as the composite results of all UDS 
within 2 weeks of delivery.  Benzodiazepine use was defined as last UDS positive for 
benzodiazepines or a history of prescription benzodiazepine use during the index pregnancy.   
 Length of treatment was transformed by taking square roots to normalize residuals.  The 
association between transformed length of treatment and various clinical and demographic 
factors was analyzed using a mixed effects linear regression.  Variables significant at the 
univariate level (p<0.20) were entered into a multivariate mixed effects model as fixed effects.  
A random intercept term was included to account for correlation among infants born to the same 
mother.  The number of neonates included in the multivariate analysis was determined by the 
number of non-missing values for length of treatment and the independent variables.  Model 
adjusted least-squares means (using observed marginal sample sizes) were calculated from 




Maternal and Neonatal Demographics.  Our cohort consisted of 185 methadone 
maintained women and 204 neonates including two sets of twins.  Thirteen women delivered 
twice and two women delivered three times.  The median length of NAS treatment was 32 days 
(range 1-122).  For unknown reasons, the average length of treatment increased between 2000-
2003, and then plateaued (Figure 1).  Maternal demographics are shown in Table 1.  With regard 
to the first delivery during the study period, 16% of women were primiparous and 84% were 
multiparous.   Most women (72.1%) were stabilized on methadone after conception.  The overall 
average maternal methadone dose was 127 mg daily.  The delivery dose of methadone was >150 
mg daily in 31.4% of women and >200 mg daily in 11.8% of women.   
 Demographics for the 204 neonates grouped by gestational age at birth are presented in 
Table 2.  Overall, the rate of preterm birth < 37 weeks was 36.3%.  As expected, birth weight and 
head circumference were significantly different among gestational age groups and increased with 
later gestational age at birth.  No other differences were noted by gestational age groups at birth.  
Univariate and Multivariate Analysis of Variables.   Table 3 shows the univariate analysis 
of maternal variables for all neonates. There was a statistically significant relationship between 
length of neonatal treatment for NAS and both concomitant benzodiazepine use (p=0.002) and 
gestational age at delivery (p<0.001).  After controlling for the possible interaction of significant 
variables (p<0.2) including length of exposure, time of initial exposure, methadone dose at 
delivery, alcohol use and gestational age at delivery, adjusted mean length of treatment was 14.4 
days longer in women who used benzodiazepines (Table 4).  As shown in Table 5, statistical 
significance remained in a subanalysis excluding preterm births less than 33 weeks gestational 
age (p<0.001).   
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 Length of treatment also increased with later gestational age at birth in the univariate 
(Table 3) and multivariate analysis (Table 4).  Adjusted mean length of treatment increased from 
11.9 days in neonates born between 23-32 6/7 weeks gestational age (n=11) to 26.2 days in 
neonates born between and 33-36 6/7 weeks (n=62) gestational age to 38.1 days in neonates born 
at term (n=128).  All pairwise group differences were significant (Bonferroni adjusted p<0.05).   
Women whose last UDS was positive for methadone and did not use any other illicit 
drugs, except marijuana, were evaluated separately (Table 5).  In these women there was no 
difference in length of treatment between infants born between 23-32 6/7 weeks and 33-36 6/7 
weeks gestational age but there were only five neonates born at less than 33 weeks gestational 
age.  Length of treatment was significantly longer in infants born 37-42 weeks gestational age 
than in infants born in either of the other two gestational age groups (p<0.001).   A similar 
pattern was seen in a subset analysis excluding births less than 33 weeks (p<0.001) (Table 5).   
  Initiation of methadone maintenance more than 10 weeks prior to delivery was associated 
with an 8.8 day increase in length of treatment (p=0.028) in the subset of neonates born after 32 
weeks gestational age but not in the other two groups (Table 5).  In this same subgroup, length of 
treatment was significantly different between delivery doses of 101-150 mg and 151-200 mg.  In 
these two dose groups length of treatment decreased from an adjusted mean of 39.0 days to 25.7 
days.  No other variables were found to be significant.   
 
Comment 
Benzodiazepine use and gestational age at birth were the two maternal variables 
identified by our study that predict the length of treatment for NAS.  Neonates exposed to 
benzodiazepines and those born at term had a significantly longer length of treatment when 
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compared to unexposed neonates or to those born at <37 weeks gestational age.  Our results also 
demonstrate that with regard to length of treatment, there is no significant relationship to 
maternal methadone dose prior to delivery.  Length of neonatal treatment could not be predicted 
by any of the other variables studied.   
Strengths of our study are that our cohort’s mean and maximum doses of methadone are 
amongst the highest reported in pregnancy in the English literature.  This is also one of the 
largest cohorts of neonates objectively diagnosed with NAS that received standardized treatment.  
Our systematic evaluation considered the relationship between length of treatment of NAS and a 
broad range of antenatal maternal variables in three categories: a) methadone maintenance (e.g. 
dose), b) substance abuse (e.g. alcohol use), c) and variables unrelated either of the other two 
categories (e.g. race).  Limitations of this approach are the facts that we did not consider the 
effect of neonatal factors such as breast feeding or different pharmacologic treatments for NAS, 
and the lack of validation of the scoring system in premature infants.   
The association of benzodiazepine use with longer length of treatment confirms earlier 
studies in smaller samples at our (6) or other (17, 18) centers.  Symptoms of benzodiazepine 
withdrawal confound neonatal abstinence score during treatment because of delayed onset as late 
as day 12 to day 21 (2, 18) and may be prolonged (19).  Opiates used in the treatment of NAS 
have no effect on withdrawal from non-opiates.  Alternative to benzodiazepines, such as 
antidepressants, for treatment of anxiety in methadone maintained mothers may be considered in 
light of these findings.  Antidepressant use, most of which were selective serotonin reuptake 
inhibitors, was not associated with longer length of treatment in our study but the relationship 
deserves further research.     
The other major finding in our study was the direct association between later gestational 
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age at birth and longer length of neonatal treatment for NAS.  Doberczak et al. first demonstrated 
more severe abstinence symptoms in term versus preterm neonates (9).  Consequently, Dysart et 
al, found that in our center, severity of symptoms translates to lengthier treatment (7).  One 
simple explanation is that term infants have greater intrauterine methadone exposure (9).  Neither 
measure of total exposure in our study, which included length of exposure and trimester of initial 
exposure, or those in other studies (13,14) were significant.  The association between gestational 
age and length of treatment is also explained by several biologically plausible mechanisms.  One 
theory is that incomplete dendritic developmental may alter clinical expression of NAS (9).  
Another explanation is slower weaning due to delayed and hepatic (7) and placental (20) 
metabolism of methadone in premature neonates.  A final explanation is increased placental 
transfer of methadone to the neonatal circulation at term (21).  The effect intravenous 
medications have on length of treatment when oral feedings are held should be considered.     
The appropriate methadone dose is controversial.  Our results demonstrate that with 
regard to length of treatment, there is no relationship to maternal methadone dose at delivery. 
Prior studies on high dose maternal methadone showed no difference in the incidence of 
treatment of NAS between high-dose (> 80 or >100 mg/d) and low dose (< 80 or <100 mg/d) 
maternal methadone groups, and less illicit drug use in the high-dose group (6, 22).  Women who 
resort to heroin while on methadone negate the positive effect of methadone on the outcomes of 
their infants (23).  The high doses in our cohort are partially a reflection of the amount of heroin 
use in our cohort and relative differences in the potency of different varieties of heroin.  The best 
explanation for why methadone dose and length of treatment are unrelated is because methadone 
metabolism is enhanced to variable degrees in the pregnancy (15).  In fact methadone trough 
levels do not correlate well with maternal dosage (24), so that maternal methadone dose should 
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be decided based on maternal symptoms, with no predetermined maximum.  Positive results may 
also be achieved in women who undergo supervised withdrawal to doses less than 20 mg daily 
(8,10).  Split daily dosing may be another alternative to maintain plasma methadone levels at 
lower overall doses (25, 26).  
In conclusion, the main findings of our study were that benzodiazepine use and later 
gestational age at birth increase length of neonatal treatment for NAS.  This study provides 
practical guidance for the clinician treating opiate-addicted pregnant women. Clinicians should 
not be hesitant to use higher doses of methadone to ameliorate withdrawal or in the 
asymptomatic woman.  Consideration should be given to avoiding benzodiazepines in 
methadone maintained mothers when a suitable alternative is available.  It is expected that some 
women will continue to use benzodiazepines illicitly and the optimal treatment for these 
neonates with concomitant opiate and benzodiazepine withdrawal is unknown.   
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Figure 1.  The trend in length of treatment over time for all neonates treated for NAS during the 
study period. 
 
 
